Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ahmed Amayem

Interventional Pain Medicine Oklahoma City, OK Medical Doctor

NPI 1992718381 CMS profile 180811

1145 Sw 74Th, Building I, Oklahoma City, OK 73139

Open in the dashboard

General payments

$5,024

146 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ahmed Amayem of Oklahoma City, OK is reported in the CMS Open Payments database as having received $5,024 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $262 4
2024 General $408 12
2023 General $820 18
2022 General $972 25
2021 General $1,112 44
2020 General $818 24
2019 General $632 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ahmed Amayem
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Ahmed Amayem were reported at $262. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Ahmed Amayem Interventional Pain Medicine median Middle half National median
2019 $632 $684 $216–$2,079 $163
2020 $818 $382 $122–$1,109 $114
2021 $1,112 $552 $167–$1,554 $132
2022 $972 $605 $187–$1,924 $149
2023 $820 $671 $195–$1,915 $160
2024 $408 $684 $206–$1,837 $164
2025 $262 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $4,839 142 payments
  2. Boston Scientific Corporation $149 2 payments
  3. Hikma Pharmaceuticals USA $35 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,929 143 payments
  2. Education $94 3 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $1,873 38 payments
  2. Proclaim Family of SCS IPGs $1,312 31 payments
  3. Proclaim IPG $965 34 payments
  4. ETERNA $256 12 payments
  5. Intracept $149 2 payments
  6. PROCLAIM Structural Heart $89 1 payment
  7. Octrode SCS Leads $81 9 payments
  8. Prodigy Family of SCS IPGs $79 8 payments
  9. IonicRF Generator $64 1 payment
  10. Kloxxado $35 2 payments
  11. Other $120 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

3,486

Median for Interventional Pain Management: 1,220

Drug cost

$75,497

Median for Interventional Pain Management: $39,344

Branded share of claims

40.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,218 $40,460
Gabapentin Generic 538 $6,412
Morphine Sulfate Er Morphine Sulfate Brand 136 $4,772
Baclofen Generic 226 $2,812
Tizanidine Hcl Generic 212 $2,671
Fentanyl Generic 28 $2,432
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 42 $1,914
Pregabalin Generic 124 $1,848
Celecoxib Generic 133 $1,527
Diclofenac Sodium Generic 84 $1,525

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$100,744

Of which drugs: $302

Medicare patients

129

Average age 66

Services billed

3,417

88 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 36%
Depression 35%
COPD 29%
Ischemic heart disease 23%
Heart failure 16%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 11 1,201 $128
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 18 39 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record